Views from key opinion leaders and a clinical trial patient on recent positive inobrodib results in relapsed refractory multiple myeloma

Potent pre-clinical and early phase clinical activity of EP300/CBP bromodomain inhibitor CCS1477 in multiple myeloma

Therapeutic Targeting of EP300/CBP by Bromodomain Inhibition in Acute Myeloid Leukemia

p300/CBP bromodomain inhibitor CCS1477 enhances the efficacy of immune checkpoint blockade therapy in cancer treatment

CCS1477, a novel p300/CBP bromodomain inhibitor, enhances efficacy of azacitidine and venetoclax in pre-clinical models of acute myeloid leukaemia and lymphoma

A Phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations

Targeting p300/CBP axis in lethal prostate cancer

Unique and Shared Epigenetic Programs of the CREBBP and EP300 Acetyltransferases in Germinal Center B Cells Reveal Targetable Dependencies in Lymphoma

Inobrodib: A novel small molecule inhibitor of p300/CBP for the treatment of acute myeloid leukaemia and multiple myeloma

An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib, a first in clinic inhibitor of the p300/CBP bromodomains, as monotherapy in patients with advanced haematological malignancies

An open-label Phase I/IIa study to evaluate the safety and efficacy of Inobrodib as monotherapy and in combination in patients with advanced solid/metastatic tumours.

Inobrodib, a potent and selective p300/CBP bromodomain inhibitor, is targeted and differentiated from BET inhibitors in prostate cancer cell lines in vitro.